期刊文献+

奥氮平在乳腺癌联合治疗方案中辅助化疗所致恶心呕吐的疗效观察 被引量:4

Antiemetic Efficacy of Olanzapine in Neoadjuvant Chemotherapy with TEC Regimen on Breast Cancer
收藏 分享 导出
摘要 目的奥氮平在乳腺癌方案新辅助化疗所致恶心呕吐的疗效观察。方法 96例乳腺癌患者被随机分为治疗组(48例)及对照组(48例),治疗组和对照组均在化疗前30min静脉滴注托烷司琼4mg及静脉注射地塞米松10mg,治疗组自化疗前24h晚上开始口服奥氮平5mg,连续服用3d,第1个化疗周期结束后评价止吐效果。结果治疗组恶心呕吐的总缓解率(87.50%)明显优于对照组(58.33%),差异具有显著统计学意义(P〈0.01)。治疗组的急性恶心呕吐的发生率(6.25%)和迟发性恶心呕吐的发生率(10.41%)均明显低于对照组(27.08%和33.33%),差异有统计学意义(P〈0.05)。结论与托烷司琼联合地塞米松相比,奥氮平联合托烷司琼和地塞米松对预防、控制乳腺癌TEC方案新辅助化疗后的急性恶心呕吐和延迟性恶心呕吐的效果较佳。 Objective To observe the antiemetic efficacy of olanzapine in neoadjuvant chemotherapy with TEC regimen on breast cancer.Methods Ninety-six cases of breast cancer patients were randomly and equally divided into treatment group and control group.Both groups were given intravenously 4mg tropisetron and 10 mg dexamethasone 30 min before chemotherapy.In the treatment group,5mg olanzapine was orally administered for three consecutive days from 24 hprior to chemotherapy,and the antiemetic efficacy was evaluated at the end of the first chemotherapy cycle.Results The total remission rate of nausea and vomiting in the treatment group(87.50%)was significantly higher than that in the control group(58.33%),and the difference was of statistical significance(P〈0.01).The incidence of acute nausea and vomiting(6.25%)and delayed nausea and vomiting(10.41%)in the treatment group was lower than that in the control group(27.08%and 33.33%).The difference between these two groups was also statistically significant(P〈0.05).Conclusion Compared to tropisetron combined with dexamethasone,olanzapine combined with tropisetron and dexamethasone shows better efficacy in preventing and controlling neoadjuvant chemotherapy-induced acute nausea and vomiting with TEC regimen on breast cancer.
作者 刘玉 高炳玉 夏立平 王昱 王超群 LIU Yu, GAO Bing-yu, XIA Li-ping, WANG Yu, WANG Chao-qun (Cancer Institute of Hainan Medical College, Haikou 570102,China)
出处 《解放军药学学报》 CAS CSCD 2017年第2期180-182,共3页 Pharmaceutical Journal of Chinese People's Liberation Army
关键词 奥氮平 乳腺癌 托烷司琼 化疗 恶心呕吐 olanzapine breast cancer tropisetron chemotherapy nausea and vomitting
作者简介 刘玉,医学硕士,主治医师。研究方向:乳腺疾病及胸部肿瘤。Tel:13307555106;Email:205489529@qq.com 通讯作者:高炳玉,Tel:13005003056;E-mail:2062145090@qq.com
  • 相关文献

参考文献6

二级参考文献53

  • 1赵忠斌,魏振平,芮伟.化疗止吐临床治疗药物新进展[J].世界临床药物,2006,27(8):480-484. 被引量:35
  • 2Chuthapisith S, Bean BE, Cowley G, et at. Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy[J]. Eur J Cancer, 2009, 45 (7) : 1274-1281. 被引量:1
  • 3van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperativechemotherapy in primary operable breast cancer: results from the european organization for research and treatment of cancer trial 10902 [J]. J Clin Oncol, 2001,19(22) :4224-4237. 被引量:1
  • 4Bastogi P, Anderson SJ, Bear HD, et al. Prvoperative chemothera- py: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27[J]. J Clin Oncol, 2008,26(5) :778-785. 被引量:1
  • 5Spielmann M, Kerbrat P, Delozier T, et al. Pirarubicin in advanced breast cancer: a French cooperative phase Ⅱ study [ J ]. Eur J Cancer, 1990,26(7) :821-823. 被引量:1
  • 6Berman E. New drugs in acute myelogenous leukemia: a review [J]. J Clin Phannacol, 1992,32(4) :296-309. 被引量:1
  • 7Henzi I,Walder B,Trainer MR.et al.Dexamethasone for the prevention of postoperative nausea and vomiting:a quantita- tive systematic review[J]. Anesth Analg,2000,90 ( 1 ): 186- 194. 被引量:1
  • 8Navari RM, Einhorm LH, Passik SD, et al. A phase Ⅱ of trial olanzapine for the prevention of chemotherapy-induced nausea and vomiting:a hoosier oncology group study [J]. Support Care Cancer, 2005,13(7 ) : 529-534. 被引量:1
  • 9Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial[J]. J Support Oncol, 2011,9(3) : 188-195. 被引量:1
  • 10Hesketh P J, Grunberg SM, Gralla R J, et al. The oral neurokinin- 1 antagonist aprepitant for the prevention of chemotherapy-inducednausea and vomiting : a multinational, randomized, double-blind, placebo-controlled trim in patients receiving high-dose cisplatin-- the Aprepitant Protocol 052 Study Group [ J ]. J Clin Oncol, 2003, 21(22) :4112-4119. 被引量:1

共引文献39

同被引文献33

引证文献4

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈
新型冠状病毒肺炎防控与诊疗专栏